lution of metabolic syndrome is associated with a progressive reduction in skeletal muscle microvessel density, known as rarefaction. Although contributing to impairments to mass transport and exchange, the temporal development of rarefaction and the contributing mechanisms that lead to microvessel loss are both unclear and critical areas for investigation. Although previous work suggests that rarefaction severity in obese Zucker rats (OZR) is predicted by the chronic loss of vascular nitric oxide (NO) bioavailability, we have determined that this hides a biphasic development of rarefaction, with both early and late components. Although the total extent of rarefaction was well predicted by the loss in NO bioavailability, the early pulse of rarefaction developed before a loss of NO bioavailability and was associated with altered venular function (increased leukocyte adhesion/rolling), and early elevation in oxidant stress, TNF-␣ levels, and the vascular production of thromboxane A2 (TxA2). Chronic inhibition of TNF-␣ blunted the severity of rarefaction and also reduced vascular oxidant stress and TxA 2 production. Chronic blockade of the actions of TxA2 also blunted rarefaction, but did not impact oxidant stress or inflammation, suggesting that TxA 2 is a downstream outcome of elevated reactive oxygen species and inflammation. If chronic blockade of TxA 2 is terminated, microvascular rarefaction in OZR skeletal muscle resumes, but at a reduced rate despite low NO bioavailability. These results suggest that therapeutic interventions against inflammation and TxA 2 under conditions where metabolic syndrome severity is moderate or mild may prevent the development of a condition of accelerated microvessel loss with metabolic syndrome. skeletal muscle perfusion; vascular remodeling; vascular reactivity; rodent models of obesity; nitric oxide bioavailability; chronic inflammation EPIDEMIOLOGICAL STUDIES HAVE clearly and consistently demonstrated that both the incidence and prevalence of the metabolic syndrome is continuing to increase in Western society and in most developed economies worldwide (4, 9, 24). Although each of the constituent systemic pathologies (e.g., impaired glycemic control, atherogenic dyslipidemia, hypertension, obesity) have been well documented to increase the risk for development of impaired vascular structure/function and peripheral vascular disease (PVD) (10,11,13,14,16,25,29,45), the significance of this multi-pathology state is that it increases the risk for individuals to develop PVD well beyond that for any single contributing element. Given the impact of PVD on life expectancy, quality of life, depression, and the direct (health care) and indirect (lost productivity) economic costs to society (3, 41, 44), considerable emphasis has been placed on not only the study of PVD and its contributing elements in human subjects but also for the detailed investigation of appropriate animal models of vasculopathy in the metabolic syndrome (1, 49, 51). However, although the existing literature is replet...